Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.

Stocks are under siege as Donald Trump's tariffs take effect. Here's where six investing gurus recommend investing your money ...

In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

The Trump Administration reversed course on plans to terminate the lease of a major Food and Drug Administration quality lab ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Piper Sandler analyst David Amsellem maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target ...

The global paresthesia treatment industry was valued at US$ 5.4 billion in 2023 and is projected to grow at a CAGR of 3.7% ...

Learn more about whether Exact Sciences Corporation or Zai Lab Limited is a better investment based on AAII's A+ Investor ...